Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral apixaban vs injectable enoxaparin after gynecologic cancer surgery
IRCT20260209068807N1Phase 3Recruiting
- Sponsor
- Urmia University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban in venous thromboembolism (VTE) and gynecological cancer (2 arms), sponsored by Urmia University of Medical Sciences. Started May 2026; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)gynecological cancer
Beyond the preview
Go deeper on IRCT20260209068807N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260209068807N1.